Biogen, Elan start Antegren Phase IIIs

BGEN and partner ELN began 2 Phase III studies of Antegren natalizumab humanized monoclonal antibody against integrin a4 to treat multiple sclerosis (MS). The trial will measure Antegren's efficacy in slowing the rate of MS disability and reducing the rate of clinical relapses in 900 patients with relapsing-remitting MS. The 2-year SENTINEL trial will compare the combination of Antegren and BGEN's marketed Avonex interferon beta-1a to Avonex alone in slowing the rate of MS disability and reducing the rate of clinical relapses in 1,200 patients with relapsing-remitting MS. ...